A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
Study Details
Study Description
Brief Summary
To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts < 250 cells/mm3 who are living in the coccidioidal endemic area.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
N/A |
Detailed Description
Patients are randomized to receive either fluconazole or placebo daily.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria
Patients must have:
-
Documented HIV infection.
-
CD4 count < 250 cells/mm3.
-
No active coccidioidomycosis or other fungal disease requiring systemic antifungal therapy.
-
Residence in area considered to be endemic for Coccidioides immitis.
-
Consent of parent or guardian if under legal age of consent.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
-
Unable to take oral medication.
-
Positive serum cryptococcal antigen.
Concurrent Medication:
Excluded:
- Systemic antifungal therapy.
Patients with the following prior conditions are excluded:
History of hypersensitivity to azole or imidazole compounds.
Prior Medication:
Excluded:
- Systemic antifungal agents within 2 weeks prior to study entry.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | McDowell Clinic | Phoenix | Arizona | United States | 85006 |
2 | Tucson Veterans Administration Med Ctr | Tucson | Arizona | United States | 85723 |
3 | Dr Lawrence Cone | Rancho Mirage | California | United States | 92270 |
Sponsors and Collaborators
- Pfizer
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 012R
- R-0266